Algernon Pharmaceuticals Inc. (AGNPF)
- Previous Close
0.0860 - Open
0.0788 - Bid --
- Ask --
- Day's Range
0.0788 - 0.0992 - 52 Week Range
0.0353 - 0.1970 - Volume
530 - Avg. Volume
12,358 - Market Cap (intraday)
2.282M - Beta (5Y Monthly) -0.54
- PE Ratio (TTM)
-- - EPS (TTM)
-0.1500 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Algernon Pharmaceuticals Inc. operates as a clinical stage pharmaceutical development company. It focuses on the areas of non-alcoholic steatohepatitis, chronic kidney disease, inflammatory bowel disease, idiopathic pulmonary fibrosis, chronic cough, pancreatic and small cell lung cancer, and acute lung injury in Canada and Australia. The company's pipeline includes Ifenprodil, which is in Phase 2b clinical trial for the treatment of idiopathic pulmonary fibrosis and chronic cough; repirinast, which is in Phase 1 clinical trial for the treatment of chronic kidney disease; and N,N-Dimethyltryptamine, which is in Phase 1 clinical trial for the treatment of strokes and traumatic brain injuries. The company was formerly known as Breathtec Biomedical, Inc. and changed its name to Algernon Pharmaceuticals Inc. in July 2015. Algernon Pharmaceuticals Inc. was incorporated in 2015 and is headquartered in Vancouver, Canada.
algernonpharmaceuticals.comRecent News: AGNPF
Performance Overview: AGNPF
Trailing total returns as of 5/14/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: AGNPF
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: AGNPF
Valuation Measures
Market Cap
1.98M
Enterprise Value
1.92M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
5.82
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-43.77%
Return on Equity (ttm)
-257.40%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-5.18M
Diluted EPS (ttm)
-0.1500
Balance Sheet and Cash Flow
Total Cash (mrq)
76.28k
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-432.31k
Research Analysis: AGNPF
Company Insights: AGNPF
AGNPF does not have Company Insights